Comparison of COBE white cell‐reduction and standard plateletpheresis protocols in the same donors

Zingsem, J.; Zimmermann, Robert; Weisbach, Volker; Glaser, Anke; Waeg, Geert van; Eckstein, Reinhold

doi:10.1046/j.1537-2995.1997.371098016443.x

Cited by 43 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also wanted to assess whether increasing the platelet yield would compromise donor safety. Apart from the relatively moderate side effects our donors suffered, the mean fall in platelet count was 63 G/L and 70 G/L corresponding to 27-30% of the predonation count, a value well within the range usually reported [14,21]. In the postdonation period, donors experienced no bleeding episodes.…”

Section: Discussionsupporting

confidence: 61%

See 1 more Smart Citation

Quality evaluation of plateletpheresis using the new AMICUS (Baxter) cell separator: Evolution of CD 62 expression

et al. 1998

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 61%

“…More recently a few reports and many abstracts have been published on the quality of platelets obtained with modern third generation cell separators providing leukodepleted products [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Quality evaluation of plateletpheresis using the new AMICUS (Baxter) cell separator: Evolution of CD 62 expression

et al. 1998

View full text Add to dashboard Cite

“…For the cell separator used in these studies, 45% to 60% (efficiency ϭ 0.45-0.60) of the platelets that pass through the separator are routinely collected. 18 Because the technical ability of the cell separator used in this study had rarely been tested at such elevated platelet counts, collection efficiency was measured for all 3 treatment groups. There was actually an increase in the collection efficiency (P Ͻ .001) at the higher platelet counts (Table 3).…”

Section: Platelet Apheresismentioning

confidence: 99%

Thrombopoietin therapy increases platelet yields in healthy platelet donors

Kuter

Goodnough

Romo

et al. 2001

Blood

View full text Add to dashboard Cite

The recombinant thrombopoietins have been shown to be effective stimulators of platelet production in cancer patients. It was therefore of interest to determine if one of these, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), could be used to increase platelet counts and consequently platelet yields from apheresis in healthy platelet donors. In a blinded, 2-cycle, crossover study, 59 platelet donors were randomized to receive a single subcutaneous injection of PEG-rHuMGDF (1 g/kg or 3 g/kg) or placebo and 15 days later undergo platelet apheresis. Donors treated with placebo had a median peak platelet count after PEG-rHuMGDF injection of 248 ؋ 10 9 /L compared with 366 ؋ 10 9 /L in donors treated with 1 g/kg PEG-rHuMGDF and 602 ؋ 10 9 /L in donors treated with 3 g/kg PEG-rHuMGDF. The median maximum percentage that platelet counts increased from baseline was 10% in donors who received placebo compared with 70% in donors who received 1 g/kg and 167% in donors who received 3 g/kg PEG-rHuMGDF. There was a direct relationship between the platelet yield and the preapheresis platelet count: Placebo-treated donors provided 3.8 ؋ 10 11 (range 1.3 ؋ 10 11 -7.9 ؋ 10 11 ) platelets compared with 5.6 ؋ 10 11 (range 2.6 ؋ 10 11 -12.5 ؋ 10 11 ) or 11.0 ؋ 10 11 (range 7.1 ؋ 10 11 -18.3 ؋ 10 11 ) in donors treated with 1 g/kg or 3 g/kg PEG-rHuMGDF, respectively. Substandard collections (<3 ؋ 10 11 platelets) were obtained from 26%, 4%, and 0% of the placebo, 1 g/kg, and 3 g/kg donors, respectively. No serious adverse events were reported; nor were there events that met the criteria for dose-limiting toxicity. Thrombopoietin therapy can increase platelet counts in healthy donors to provide a median 3-fold more apheresis platelets compared with untreated donors. (Blood. 2001;98:1339-1345)

show abstract

“…Nowadays, apheresis techniques are able to reduce leucocyte contamination in platelets to levels comparable with those obtained after filtration [52]. There are no randomised studies in man comparing the incidence of HLA alloimmunisation after pre– and post–storage–filtered blood components.…”

Section: Approaches To Prevent Hla Alloimmunisationmentioning

confidence: 99%

Prevention and Management of Platelet Transfusion Refractoriness

Novotný¹

1999

Vox Sanguinis

View full text Add to dashboard Cite

Platelet transfusion refractoriness is a major complication of long–term platelet supportive care. Refractoriness may lead to fatal bleeding complications in thrombocytopenic patients. Major factors involved are factors related to the clinical condition of the patient as well as HLA alloimmunisation. Non–alloimmune factors may occur in up to 80% of the patients. However, platelet transfusion outcome is impaired in only 50% of the patients having these conditions. HLA alloimmunisation has been convincingly reduced by the use of leucocyte–depleted transfusions. UV–B irradiation of platelet transfusions may be alternatively used to reduce HLA alloimmunisation. Despite these measures, patients with a history of pregnancy or non–leucocyte–depleted transfusions form HLA antibodies in a high proportion (up to 50%). HPA antibodies play a minor but relatively important role in patients with HLA antibodies. ABO antibodies may play a role in refractoriness, which can be abolished by transfusion of ABO–identical platelets. Screening for the presence of HLA and/or HPA antibodies is indicated in case of transfusion failure after ABO–identical or HLA–matched platelets. If no alloantibodies are detected, further analysis to define a role of drug– related or autoantibodies is required. In case of HLA and/or HPA alloimmunisation associated with refractoriness, matched platelet transfusions are indicated. In case of non–alloimmune factors associated with increased platelet consumption, increasing the transfusion frequency can be considered. Additional investigations are still necessary to define risk factors for secondary HLA alloimmunisation and refractoriness due to non–immune factors to further decrease the incidence of refractoriness.

show abstract

Comparison of COBE white cell‐reduction and standard plateletpheresis protocols in the same donors

Cited by 43 publications

References 31 publications

Quality evaluation of plateletpheresis using the new AMICUS (Baxter) cell separator: Evolution of CD 62 expression

Quality evaluation of plateletpheresis using the new AMICUS (Baxter) cell separator: Evolution of CD 62 expression

Thrombopoietin therapy increases platelet yields in healthy platelet donors

Prevention and Management of Platelet Transfusion Refractoriness

Contact Info

Product

Resources

About